SEARCH

SEARCH BY CITATION

References

  • Appleton RE, Peters ACB, Mumford JP, Shaw DE. (1999) Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 40:16271633.
  • Ben-Menachem E. (2002) Vigabatrin. In LevyRH, MattsonRH, MeldrumBS, PeruccaE (Eds) Antiepileptic drugs. 5th ed. Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, pp. 855863.
  • Best JL, Acheson JF. (2005) The natural history of vigabatrin associated visual field defects in patients electing to continue their medication. Eye 19:4144.
  • Bjornaes H, Stabell K, Henriksen O, Loyning Y. (2001) The effects of refractory epilepsy on intellectual functioning in children and adults: a longitudinal study. Seizure 10:250259.
  • Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ, Ben-Menachem E, Napoliello MJ, Sherry KM, Szabo GK. (1987) Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology 37:184189.
  • Bruni J, Guberman A, Vachon L, Desforges C, the Canadian Vigabatrin Study Group. (2000) Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicenter study. Seizure 9:224232.
  • Chiron C, Dulac O, Beaumont D, Palacios L, Pajot N, Mumford J. (1991) Therapeutic trial of VGB in refractory infantile spasms. J Child Neurol 6(suppl 2):2S522S59.
  • Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O. (1997) Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 26:389395.
  • Cohen JA, Fisher RS, Brigell MG, Peyster RG, Sze G. (2000) The potential for vigabatrin-induced intramyelinic edema in humans. Epilepsia 41:148157.
  • Cossette P, Riviello JJ, Carmant L. (1999) ACTH versus vigabatrin therapy in infantile spasms: a retrospective study. Neurology 52:16911694.
  • Dean C, Mosier M, Penry K. (1999) Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 40:7482.
  • DeToledo JC, Bittman RM, Collins SD, Sagar SM. (2006) Vigabatrin-induced visual field defect: update 2007. Poster presented at: 61st Annual Meeting of the American Epilepsy Society, November 30–December 3, Philadelphia, Pennsylvania.
  • Eke T, Talbot JF, Lawden MC. (1997) Severe persistent visual field constriction associated with vigabatrin. BMJ 314:180.
  • Elterman RD, Shields WD, Mansfield KA, Nakagawa J. (2001) Randomized trial of vigabatrin in patients with infantile spasms. Neurology 57:14161421.
  • Fledelius HC. (2003) Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal. Acta Ophthalmol Scand 81:4146.
  • French JA, Mosier M, Walker S, Sommerville K, Sussman N, the Vigabatrin Protocol 024 Investigative Cohort. (1996) A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 46:5461.
  • Garcia Pastor A, Garcia-Zarza E, Peraita Adrados R. (2000) Acute encephalopathy and myoclonic status induced by vigabatrin monotherapy. Neurologia 15:370374.
  • Gonzalez PA, Parks S, Kelly K, Brodie M. (2004) Progression of neuro-retinal toxicity in patients on vigabatrin: objective assessment using the wide field multifocal electroretinogram. Epilepsia 45(suppl 7):188. [Abstract B.07.]
  • Gram L, Klosterskov P, Dam M. (1985) Gamma-vinyl GABA: a double-blind, placebo-controlled trial in partial epilepsy. Ann Neurol 17: 262266.
  • Granström ML, Gaily E, Liukkonen E. (1999) Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms. Epilepsia 40:950957.
  • Harding GF, Wild JM, Robertson KA, Rietbrock S, Martinez C. (2000) Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology 55:347352.
  • Harding GF, Spencer EL, Wild JM, Conway M, Bohn RL. (2002) Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. Neurology 58:12611265.
  • Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TTJM, Van Veelen CWM. (2000) Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin. Br J Ophthalmol 84:788790.
  • Jedrzejczak J, Dlawichowska E, Owczarek K, Majkowski J. (2000) Effect of vigabatrin addition on carbamazepine blood serum levels in patients with epilepsy. Epilepsy Res 39:115120.
  • Kalviainen R, Nousiainen I. (2001) Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 15:217230.
  • Kinirons P, Cavalleri GL, O’Rourke D, Doherty CP, Reid I, Logan P, Liggan B, Delanty N. (2006) Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia 47:311317.
  • Krauss GL, Johnson MA, Miller NR. (1998) Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 50:614618.
  • Krauss GL, Miller NR. (1999) Vigabatrin: an effective antiepilepsy drug – balancing the risk of visual dysfunction. Ann Pharmacother 33:13671368.
  • Levinson DF, Devinsky O. (1999) Psychiatric adverse events during vigabatrin therapy. Neurology 53:15031511.
  • Loiseau P, Hardenberg JP, Pestre M, Guyot M, Schechter PJ, Tell GP. (1986) Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia 27:115120.
  • Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O’Callaghan FJK, Verity CM, Osborne JP. (2004) The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicenter, randomized controlled trial. Lancet 364:17731778.
  • Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O’Callaghan FJK, Verity CM, Osborne JP. (2005) The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicenter randomized trial. Lancet Neurol 4:712717.
  • Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K, Baram TZ, Duchowny M, Hirtz D, Pellock JM, Shields WD, Shinnar S, Wyllie E, Snead OC 3rd. (2004) Practice parameter. Medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 62:16681681.
  • Mauri-Llerda JA, Iniguez C, Tejero-Juste C, Santos-Lasaosa S, Escalza-Cortina I, Ascaso-Puyuelo J, Abad-Alegría F, Morales-Asín F. (2000) Alterations in visual field changes secondary to treatment with vigabatrin. Rev Neurol 31:11041108. [In Spanish.]
  • Mohanraj R, Norrie J, Stephen LJ, Kelly K, Hitiris N, Brodie MJ. (2006) Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol 5:481487.
  • Nashef L, Fish DR, Sander JW, Shorvon SD. (1995) Incidence of sudden unexpected death in an adult outpatient cohort with epilepsy at a tertiary referral center. J Neurol Neurosurg Psychiatry 58:462464.
  • National Institute for Clinical Excellence. (2004) Clinical guideline 20. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. National Institute for Clinical Excellence, London, UK.
  • Nousiainen I, Mantyjarvi M, Kalviainen R. (2001) No reversion in vigabatrin-associated visual field defects. Neurology 57:19161917.
  • Ovation Pharmaceuticals, Inc. (1993a) Data on file. Clinical study report. Protocol 71754-3-C-024; NDA 20-427, v1.94.
  • Ovation Pharmaceuticals, Inc. (1993b) Data on file. Clinical study report. Protocol 71754-3-C-025; NDA 20-427, v1.114.
  • Ovation Pharmaceuticals, Inc. (2005) Data on file. Clinical study report. Protocol 1-A; IND 47,707, v1.0.
  • Ovation Pharmaceuticals, Inc. (2007a) Data on file. Sabril (vigabatrin) tablets safety update NDA 20-427. December 28, 2007.
  • Ovation Pharmaceuticals, Inc. (2007b) Data on file. Vigabatrin-induced retinal dysfunction.
  • Ovation Pharmaceuticals, Inc. (2007c) Data on file. National Health Service of Scotland Study, University of Glasgow, Glasgow.
  • Pearl PL, Molloy-Wells E, McClintock WM, Vezina LG, Conry JA, Elling NJ, Tsuchida T, Heath C, Cushner-Weinstein S, Kolodgie M, Weinstein SL, Gaillard WD. (2006) MRI abnormalities associated with vigabatrin therapy: higher risk in infants? Poster presented at the Annual Meeting of the American Epilepsy Society, San Diego, CA. [Abstract number PH.04.]
  • Petroff OAC, Behar KL, Mattson RH, Rothman DL. (1996) Human brain γ-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. J Neurochem 67:23992404.
  • Ponjavic V, Andreasson S. (2001) Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol 102:6372.
  • Rimmer EM, Richens A. (1984) Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet 1:189190.
  • Sander JW, Hart YM, Trimble MR, Shorvon SD. (1991) Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry. 54:435439.
  • Scottish Intercollegiate Guidelines Network. (2005) Diagnosis and management of epilepsies in children and young people: a national clinical guideline (81). Scottish Intercollegiate Guidelines Network, Edinburgh, UK.
  • Spencer EL, Harding GF. (2003) Examining visual field defects in the pediatric population exposed to vigabatrin. Doc Ophthalmol 107:281287.
  • Sperling MR. (2004) The consequences of uncontrolled epilepsy. CNS Spectr 9:98101.
  • Tartara A, Manni A, Galimberti CA, Hardenberg J, Orwin J, Perucca E. (1986) Vigabatrin in the treatment of epilepsy: a double-blind placebo-controlled study. Epilepsia 27:717723.
  • Tassinari CA, Michelucci R, Ambrosetto G, Salvi F. (1987) Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. Arch Neurol 44:907910.
  • University of Toronto. (2007) Data on file. Hospital for Sick Children, Toronto, Ontario.
  • Veggiotti P, De Agostini G, Muzio C, Termine C, Baldi PL, Ferrari Ginevra O, Lanzi G. (1999) Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study. Acta Neurol Scand 99:142146.
  • Versino M, Veggiotti P. (1999) Reversibility of vigabatrin-induced visual field defect. Lancet 354:486.
  • Vigevano F, Cilio MR. (1997) Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 38:12701274.
  • Villeneuve N, Soufflet C, Plouin P, Chiron C, Dulac O. (1998) Treatment of infantile spasms with vigabatrin as first-line therapy and in monotherapy: apropos of 70 infants. Arch Pediatr 5:731738.
  • Westall CA, Nobile R, Morong S, Buncic JR, Logan WJ, Panton CM. (2003) Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc Ophthalmol 107:299309.
  • Wild JM, Martinez C, Reinshagen G, Harding GF. (1999) Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40:17841794.
  • Wild JM, Ahn H-S, Baulac M, Bursztyn J, Chiron C, Gandolfo E, Safran AB, Schiefer U, Perucca E. (2007) Vigabatrin and epilepsy: lessons learned. Epilepsia 48:13181327.
  • Xavier M, Bento MS, Pereira DP, De Almeida JM. (2000) Acute psychotic disorder associated with vigabatrin. Acta Med Port 13:111114.